Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hinoman is an Israeli biotechnology and AgTech company focused on the scalable cultivation of Mankai, a nutrient-dense aquatic plant. Mankai is a proprietary strain of Wolffia globosa, often referred to as the world's smallest vegetable, containing a complete protein profile and essential micronutrients. The company employs a sophisticated, closed-loop hydroponic system that allows for precise control over growth conditions and ensures a sustainable, year-round harvest. Hinoman's business model includes a strategic partnership with Ajinomoto, which provides the Japanese conglomerate with exclusive distribution rights in Japan and a minority equity stake. Clinical studies have highlighted Mankai's efficacy in improving postprandial glucose levels and providing highly bioavailable iron, positioning it as a functional food for metabolic health. The company targets the global plant-based protein and superfood markets, catering to both consumer health and clinical nutrition sectors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hinoman Ajinomoto.